News & Updates

Show Multimedia Only

No benefit seen for aspirin in breast cancer

03 May 2024 by

Taking aspirin in the adjuvant setting does not appear to lower the risk of recurrence or improve survival in patients with high-risk nonmetastatic breast cancer, as shown in the results of the phase III Alliance A011502 trial.

No benefit seen for aspirin in breast cancer

03 May 2024

Ranolazine plus AAD helps maintain sinus rhythm after DCCV in persistent AF

03 May 2024 by

Treatment with ranolazine in combination with class III antiarrhythmic drugs (AADs) is associated with improved maintenance of sinus rhythm (SR) 1 year after DC cardioversion (DCCV) relative to class III AAD alone, according to a study presented at EHRA 2024.

Ranolazine plus AAD helps maintain sinus rhythm after DCCV in persistent AF

03 May 2024

What are the long-term effects of ARBs, ACEIs in patients with Crohn’s disease?

03 May 2024

Use of angiotensin-converting enzyme inhibitors (ACEIs) often results in a poorer disease course at 5 and 10 years, whereas treatment with angiotensin receptor blockers (ARBs) is associated with fewer cases of corticosteroid use at 10 years, reports a study involving patients with Crohn’s disease (CD).

What are the long-term effects of ARBs, ACEIs in patients with Crohn’s disease?

03 May 2024

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

03 May 2024 by

In individuals with advanced solid malignancies, subcutaneous (SC) amivantamab administered once a month is associated with fewer infusion-related reactions (IRRs) and offers more convenience than the IV formulation, the phase Ib PALOMA study suggest.

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

03 May 2024

$BP-lowering meds up risk of fractures in older people$

BP-lowering meds up risk of fractures in older people

02 May 2024

Older people who are initiating blood pressure (BP)-lowering medications appear to be at heightened risk of fractures, especially those who have dementia, as shown in a retrospective cohort study.

BP-lowering meds up risk of fractures in older people

02 May 2024

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

02 May 2024 by

Use of landiolol, a highly selective and short-acting beta-1 blocker, demonstrates adequate safety and efficacy in terms of heart rate control among patients suffering from atrial tachyarrhythmias (ATs) and left ventricular (LV) dysfunction, suggest the results of a meta-analysis presented at EHRA 2024.

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

02 May 2024

Dostarlimab-chemo a new SoC for endometrial cancer?

02 May 2024 by

In the second interim analysis of part 1 of the phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, dostarlimab plus carboplatin/paclitaxel (CP) chemotherapy delivered a significant survival benefit in women with primary advanced or recurrent endometrial cancer.

Dostarlimab-chemo a new SoC for endometrial cancer?

02 May 2024

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

02 May 2024

In women undergoing autologous in vitro fertilization (IVF) for fertility treatment, ovulatory suppression with medroxyprogesterone acetate proves effective, with cycle and reproductive outcomes similar to that with gonadotropin-releasing hormone (GnRH) antagonist and the advantage of being cheaper, according to a study.

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

02 May 2024

Oral lasofoxifene helps improve genitourinary syndrome of menopause

01 May 2024

Oral lasofoxifene at either 0.25 or 0.5 mg daily confers benefits on genitourinary syndrome of menopause, with pooled data from two phase III trials showing significant improvements in vaginal signs or symptoms while having a favourable safety profile.

Oral lasofoxifene helps improve genitourinary syndrome of menopause

01 May 2024

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

30 Apr 2024

Children who were exposed antenatally to betamethasone as opposed to placebo are not necessarily at a disadvantage in terms of neurodevelopment outcomes, as shown in a follow-up to the Antenatal Late Preterm Steroids (ALPS) trial.

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

30 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

No benefit seen for aspirin in breast cancer

No benefit seen for aspirin in breast cancer

Ranolazine plus AAD helps maintain sinus rhythm after DCCV in persistent AF

Ranolazine plus AAD helps maintain sinus rhythm after DCCV in persistent AF

What are the long-term effects of ARBs, ACEIs in patients with Crohn’s disease?

What are the long-term effects of ARBs, ACEIs in patients with Crohn’s disease?

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

BP-lowering meds up risk of fractures in older people

BP-lowering meds up risk of fractures in older people

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

Dostarlimab-chemo a new SoC for endometrial cancer?

Dostarlimab-chemo a new SoC for endometrial cancer?

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

Oral lasofoxifene helps improve genitourinary syndrome of menopause

Oral lasofoxifene helps improve genitourinary syndrome of menopause

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment